GeneTherapyLive’s Weekly Rewind – January 28, 2022

Welcome to GeneTherapyLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. HLA LOH Prevalent in GI Cancers, Identifies Future Study Participants

Investigators have identified the prevalence of Human Leukocyte Antigen Loss of Heterozygosity (HLA LOH) in gastrointestinal tumors as part of the BASECAMP-1 study (NCT04981119) for future use of Tmod CAR T-cell therapy.

2. Omidubicel BLA Submission for Hematologic Malignancies Expected First Half of 2022

Gamida Cell is planning to complete their BLA for omidubicel (NiCord), a cell therapy for bone marrow transplant in patients with hematologic malignancies, in the first half of 2022 following positive Type B meeting correspondence from the FDA.

3. Improving Outcomes in Hemophilia WithFitusiran: Guy Young, MD

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed advantages of the siRNA therapeutic. He discussed unmet needs in hemophilia B and the decent population included in the ATLAS-INH study.

4. Around the Helix: Gene and Cell Therapy Company Updates - January 26, 2022

GeneTherapyLive’s Around the Helix is your chance to catch up with the latest news in gene and cell therapies, including partnerships, pipeline updates, and more.

5. DLBC Lymphoma CAR T Therapy Granted RMAT and Fast Track Designations

The FDA has granted regenerative medicine advanced therapy and fast track designation to C-CAR039 for patients with relapsed or refractory diffuse large B-cell lymphoma.